Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Pharmaceutical Research
|
June 1, 2013
Development and characterization of nanostructured mists with potential for actively targeting poorly water-soluble compounds into the lungs
Jerry Nesamony, Ashish Kalra, Mohamed S Majrad, et al.
Advances in Therapy
|
May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Doreen Barrett, Sanela Bilic, Yung Chyung, et al.
Cancer Research
|
December 1, 2017
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
Huang-Chiao Huang, Imran Rizvi, Joyce Liu, et al.
Neuro-Oncology
|
December 25, 2012
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Pin-Yuan Chen, Tomoko Ozawa, Daryl C Drummond, et al.
Science Signaling
|
July 2, 2009
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis
Birgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, et al.
Science Translational Medicine
|
March 28, 2020
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Constance J Martin, Abhishek Datta, Christopher Littlefield, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
Jessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.
NPJ Systems Biology and Applications
|
July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Journal of the National Cancer Institute
|
December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Pharmaceutical Research
|
June 1, 2013
Development and characterization of nanostructured mists with potential for actively targeting poorly water-soluble compounds into the lungs
Jerry Nesamony, Ashish Kalra, Mohamed S Majrad, et al.
Advances in Therapy
|
May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Doreen Barrett, Sanela Bilic, Yung Chyung, et al.
Cancer Research
|
December 1, 2017
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
Huang-Chiao Huang, Imran Rizvi, Joyce Liu, et al.
Neuro-Oncology
|
December 25, 2012
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Pin-Yuan Chen, Tomoko Ozawa, Daryl C Drummond, et al.
Science Signaling
|
July 2, 2009
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis
Birgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, et al.
Science Translational Medicine
|
March 28, 2020
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Constance J Martin, Abhishek Datta, Christopher Littlefield, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
Jessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.
NPJ Systems Biology and Applications
|
July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
Journal of the National Cancer Institute
|
December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Page
of 2